Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.

Authors
Type
Published Article
Journal
JAIDS Journal of Acquired Immune Deficiency Syndromes
1525-4135
Publisher
Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins
Publication Date
Volume
55
Issue
3
Pages
323–329
Identifiers
DOI: 10.1097/QAI.0b013e3181eb376b
PMID: 20683270
Source
Medline
License
Unknown

Abstract

Fixed-dose combination tablet containing COBI 150 mg resulted in desired high EVG Ctau concentrations and clinically equivalent tenofovir and FTC exposures relative to currently approved individual agents and was thus selected for subsequent evaluation.

Statistics

Seen <100 times